PDX model details
| PDX ID | 305R Cx |
|---|---|
| Host Strain(and Source) | NSG Source: Monash University |
| Host Strain Immune system Humanized | NO |
| Host Type | Castrate |
| Graft Site | Subcutaneous |
| Current Generation (* indicates number of generations grown in Castrate host) |
45 (22*) |
| Average PDX Generation Time (days +/- SEM) | 41 ± 1 |
| Tumour preparation | Tumor solid |
| Tumour Characterization Technology | Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin | Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed | Routine QA every 2-3 passages |
| Associated meta data | |
| PDX model availability | Yes (fixed, frozen or cryopreserved tissue) |
| Governance restriction for distribution | Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID | 34413304 |
| Markers | 305R Cx |
|---|---|
| AR | N |
| PSA | N |
| PSMA | N |
| NE | Y |
| ERG | N |
This table displays curated CNVs
| PDX ID | Gene Symbol | CNV Log2 | CNV Copy | CNV Call | Experiments name | Platform | Reference genome |
|---|---|---|---|---|---|---|---|
| 305R Cx | RB1 | -28.688 | 4.630e-09 | Homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 305R Cx | PTEN | -18.516 | 5.340e-06 | Homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 305R Cx | CDKN1B | -1.011 | 0.993 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 305R Cx | BRCA2 | -0.991 | 1.006 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 305R Cx | CDH1 | -0.967 | 1.023 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 305R Cx | ZFHX3 | -0.967 | 1.023 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 305R Cx | FANCA | -0.967 | 1.023 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 305R Cx | RB1 | -0.953 | 1.033 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 305R Cx | SUFU | -0.943 | 1.040 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 305R Cx | TP53 | -0.938 | 1.044 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 305R Cx | PTEN | -0.938 | 1.044 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 305R Cx | SETD2 | -0.903 | 1.070 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 305R Cx | KEAP1 | 0.526 | 2.880 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 305R Cx | PIK3R2 | 0.526 | 2.880 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 305R Cx | PALB2 | 0.544 | 2.915 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 305R Cx | USP7 | 0.544 | 2.915 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 305R Cx | MYC | 3.151 | 17.759 | Gain-High | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
Clinical Information
| Sample Number | 305R |
|---|---|
| Sample Site | Prostate |
| Sample source | Radical prostatectomy |
| Pathology Tumour Diagnosis | Adenocarcinoma |
| Gleason Score | 9 |
| Primary Gleason Score | 5 |
| Secondary Gleason Score | 4 |
| Tertiary Gleason Score | None |
| ISUP Grade Group | 5 |
| Tumour Grade | pT3bN1 |
| D'Amico Risk Classification | 7 |
| Tumour Volume (in cc) | 73.4 |
| Treatment Prior to Specimen Collection | None |
Patient Information
| Patient Number | 305 |
|---|---|
| Sex | Male |
| Diagnosis | Prostate Cancer |
| PSA at diagnosis (ng/mL) | 2 |
| Consent to share data | |
| Patient Tumour Collection (Current Model) | |
|---|---|
| Tumour sample ID | 305R |
| Patient Age (binned in 5 year age groups) | 75-79 |
This table displays curated sequence variants
| PDX ID | Gene Symbol | Total Read Depth | Alternate Frequency | Consequence | Exon | GnomAD AF | CADD PHRED score | ClinVar significance | Platform | Experiments Name | Reference | Library Type | Instrument Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 305R Cx | TP53 | 303 | 1.0 | Stop gained | '6/11 | 4.06E-06 | 36 | Pathogenic | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 305R Cx | APC | 580 | 0.53 | Missense variant | '16/16 | . | 22 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 305R Cx | HGF | 436 | 0.51 | Missense variant | '18/18 | . | 24.4 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 305R Cx | MGAM | 551 | 0.5 | Missense variant | '21/48 | . | 15.37 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 305R Cx | GRM7 | 668 | 0.48 | Missense variant | '8/10 | . | 24.3 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 305R Cx | DST | 672 | 0.48 | Missense variant | '11/84 | . | 26.2 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 305R Cx | NF1 | 400 | 0.42 | Missense variant,splice region variant | '7/58 | . | 25.8 | Uncertain significance | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
This table displays drug response data
qd->once daily; qwk->once weekly The table can be sorted by any field. However, please note that when you click on a column header to sort, there might be a brief delay
qd->once daily; qwk->once weekly The table can be sorted by any field. However, please note that when you click on a column header to sort, there might be a brief delay
| PDX ID | Treatment1 | Dose (mg/kg) | Frequency | Treatment2 | Dose (mg/kg) | Frequency | Response |
|---|---|---|---|---|---|---|---|
| 305R Cx | Carboplatin | 50 | qwk | NA | NA | NA | Response |
| 305R Cx | Talazoparib | 0.33 | qd | Carboplatin | 50 | qwk | Response |
| 305R Cx | Talazoparib | 0.33 | qd | NA | NA | NA | No response |